Top Gainers for 7-5-23: $ALLR $BTAI

$ALLR - Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients: https://finance.yahoo.com/news/initial-data-allarity-phase-2-134500446.html

$BTAI - BTAI: Positive Data for TRANQUILITY II Trial Overshadowed by Possible Trial Mismanagement…: https://finance.yahoo.com/news/btai-positive-data-tranquility-ii-142000996.html